John, Mike & Tom's <b>Wild World of Stocks</b> Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : John, Mike & Tom's Wild World of Stocks

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: wlheatmoon who wrote (434)	3/9/2000 8:23:00 AM
From: John Pitera	Read Replies (1) of 2850

I see that the genome stocks are finally cooling off a bit. It will be interesting to see where the buying interest comes back into stocks such as HYSQ. PFE may be a real sleeper. If the genome sequencing is to yield medical benefits, PFE should be well positioned . CRA says it's 90% of the way to completing the sequencing, and PFE has an exclusive 5 year license to utilize the CRA database. Hence they could be uniquely positioned to roll-out products from this technological breakthrough. the other companies working on the sequencing are back towards only a 50% completion level. John

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next